Sodium alginate, calcium carbonate, and guar gum were mixed with oils such as olive oil (OO), sesame oil (SO), and medium chain triglyceride (MCT). The oily formulations were found to simplify the preparation of in situ floating gel. This was the aim of this study using ketoconazole (keto) as a model drug. The investigations for the floating property were established by In vitro gelling capacity study and In vitro floating study. Additionally, in vitro release study was applied to find the best formulations to delay the release of keto. Then, selected formulations were studied by FTIR and SEM. Lastly, in vivo gelation was performed to examine the gelation in the rat’s stomach. The results showed all formulations were floating after successful gelation as the least amount of sodium alginate to gel oils was 20% w/w. The gels in SO and OO were better than MCT in delaying keto release, and 30% w/w sodium alginate in SO was the best to delay the release of keto within 8 hours of the release study. Selected gels showed interactions between the keto molecules and the molecules of the gel contents by FTIR study, and SEM showed a difference in the internal structure of selected formulations. Lastly, the 30% w/w sodium alginate in SO proved to gel and remain in the rat's stomach in the following periods: 30 min, 1 hour, 2 hours, and after 8 hours. Oily suspension formulations showed floating properties in the stomach and slowed the release of keto and specifically 30% w/w of sodium alginate in SO.

Mucopolysaccharidosis I (MPS I) or Hurler and Mucopolysaccharidosis VI (MPS VI) or Maroteaux-Lamy syndrome are infrequent genetic disorder inherited as an autosomal recessive disease attributed to genetic   variants genetic variant causing α-L iduronidase (IDUA) and arylsulfatase B (ARSB)enzyme deficiency, respectively.  Here, two cases of children suffering from MPS disorder were described, the first case was MPS I while the second case was MPS VI and both cases were treated with allogenic Hematopoietic Stem Cell Transplantation approach in order to limit skeletal deterioration and retard neurocognitive alterations and hence, improve the quality of life of affected children. Following Transplantations outcomes reveal a full engraftment of donor cells as well as improvement of recipient enzymatic activity, enzyme replacement therapy post-transplantation will augment transplantation clinical outcomes. Transplantation will be more successful if the disease diagnosed early before the severe irreversible symptoms ensue.

Objective: The scope of this study is to evaluate the influence of metal nanoparticles application on pharmaceutical properties and biologic activity of antifungal drug, metronidazole (MTZ). Method: Metal nanoparticles used in the study, bismuth sulfide (Bi2S3) used as the nanocarriers for metronidazole (MTZ) and they were synthesized by chemical co-precipitation method. Drug loading on Bi2S3 nanoparticles, lattice property alteration and average particles sizes were evaluated using fourier transform infra-red (FTIR) spectroscopy, atomic force microscopy(AFM), and powder x-ray diffraction(PXRD). The evaluation of the release of MTZ from Bi2S3 nanoparticles was carried out using USP type II rotating puddle apparatus. The antimicrobial activity of MTZ before and after loading was carried out by disc diffusion method against two aerobic gram +ve and one aerobic gram –ve bacteria, in addition to two fungi. Result: This study showed successful loading process as well as particles size reduction of MTZ after loading on Bi2S3 nanoparticles. In vitro release study showed significant* increase in solubility and dissolution of MTZ after loading on Bi2S3 nanoparticles. MTZ showed significant* increase in antibacterial (against gram +ve aerobic staphylococcus aureus and bacillus subtilis) and antifungal (Candida glabrata and Candida tropicalis) activities after loading process. Conclusion: Nanotechnology was applied successfully to improve both, solubility and biologic activity of the model drug used, metronidazole (MTZ).

Metastatic breast cancer patients may acquire oral morbidity from therapeutic procedures. A common adverse event (AE) of the Mammalian target of rapamycin (mTOR) inhibitor is associated stomatitis (mIAS) secondary to mTOR inhibitor therapy, which have a negative impact on the quality of life, therapy adherence and health care expenses. A multidisciplinary team strategy is essential for reducing mIAS and capitalize on therapy advantages for breast cancer patients. We discuss the pathophysiology, diagnosis, and natural history of mIAS in this review. In the context of promoting a coordinated team care approach to optimizing patient care, current and new management policies are outlined for the prevention and treatment of mIAS. Types of Studies Reviewed: We piloted different research from 2007 through 2019 using the terms “stomatitis,” “mIAS,” “mTOR,” “everolimus,” “oral care.” and “metastatic breast cancer,” We have chosen papers from peer-reviewed journals reporting controlled trials and evidence-based guidance. Results: Cytototoxic chemical or radiation therapy causes, clinical presentation, and paradigms of therapy can distinguish mIAS from mucositis. The continuum of patient oral health care may include specific preventive and therapeutic leadership approaches. Practical consequences: Oral health providers are at the forefront of oral health care for patients who have metastatic breast cancer and are uniquely positioned to deliver patient education, to advocate precise reporting of mIAS, and to encourage early identification, monitoring and rapid intervention to reduce the serious and time-limiting dose of this manageable AE.

No abstract